Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zebularine is a chemically stable nucleoside analog of cytidine that acts as a transition state analog inhibitor of cytidine deaminase and an inhibitor of DNA methyltransferase. It forms covalent complexes with DNA methyltransferases (DNMTs), thereby inhibiting their activity, which leads to the demethylation and reactivation of silenced genes, particularly tumor suppressor genes in cancer cells. Zebularine displays anti-tumor properties both in vitro and in vivo, including inhibition of cell proliferation, induction of apoptosis, antiangiogenic effects, and potential for epigenetic therapy in cancer chemoprevention. It has also been shown to potentiate the effects of other epigenetic therapeutics such as vorinostat[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zebularine.